Clinical Trial Update: ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC

View source ↗

Summary

This clinical trial update covers ALK, ROS1, and MET mutations detected in plasma ctDNA from non-small cell lung cancer patients, including stage III and metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of Lung
• Non-small Cell Lung Cancer

Snippet

Sponsor: First People's Hospital of Hangzhou | Conditions: Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic | Status: UNKNOWN